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Abstract
Background: The identification of signaling pathways that affect the cancer stem-like phenotype may provide
insights into therapeutic targets for combating embryonal rhabdomyosarcoma. The aim of this study was to
investigate the role of the MEK/ERK pathway in controlling the cancer stem-like phenotype using a model of
rhabdospheres derived from the embryonal rhabdomyosarcoma cell line (RD).
Methods: Rhabdospheres enriched in cancer stem like cells were obtained growing RD cells in non adherent
condition in stem cell medium. Stem cell markers were evaluated by FACS analysis and immunoblotting. ERK1/2,
myogenic markers, proteins of DNA repair and bone marrow X-linked kinase (BMX) expression were evaluated by
immunoblotting analysis. Radiation was delivered using an x-6 MV photon linear accelerator. Xenografts were
obtained in NOD/SCID mice by subcutaneously injection of rhabdosphere cells or cells pretreated with U0126 in
stem cell medium.
Results: MEK/ERK inhibitor U0126 dramatically prevented rhabdosphere formation and down-regulated stem cell
markers CD133, CXCR4 and Nanog expression, but enhanced ALDH, MAPK phospho-active p38 and differentiative
myogenic markers. By contrast, MAPK p38 inhibition accelerated rhabdosphere formation and enhanced phospho-active
ERK1/2 and Nanog expression. RD cells, chronically treated with U0126 and then xeno-transplanted in NOD/SCID mice,
delayed tumor development and reduced tumor mass when compared with tumor induced by rhabdosphere cells.
U0126 intraperitoneal administration to mice bearing rhabdosphere-derived tumors inhibited tumor growth . The
MEK/ERK pathway role in rhabdosphere radiosensitivity was investigated in vitro. Disassembly of rhabdospheres was
induced by both radiation or U0126, and further enhanced by combined treatment. In U0126-treated rhabdospheres,
the expression of the stem cell markers CD133 and CXCR4 decreased and dropped even more markedly following
combined treatment. The expression of BMX, a negative regulator of apoptosis, also decreased following combined
treatment, which suggests an increase in radiosensitivity of rhabdosphere cells.
Conclusions: Our results indicate that the MEK/ERK pathway plays a prominent role in maintaining the stem-like
phenotype of RD cells, their survival and their innate radioresistance.
Thus, therapeutic strategies that target cancer stem cells, which are resistant to traditional cancer therapies, may benefit




1Department of Biotechnological and Applied Clinical Sciences, University of
L’Aquila, Via Vetoio, Coppito 2, 67100 L’Aquila, Italy
Full list of author information is available at the end of the article
© 2016 Ciccarelli et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ciccarelli et al. Molecular Cancer  (2016) 15:16 
DOI 10.1186/s12943-016-0501-y
Background
Rhabdomyosarcoma is the most common soft tissue
tumor in childhood, accounting for more than half of
all soft tissue sarcomas in children [1, 2]. The embry-
onal rhabdomyosarcoma subtype (ERMS) accounts for
about 70 % of all rhabdomyosarcoma cases. In ERMS
tumors, the Ras pathway is frequently mutated [3]. Dys-
regulation of the Ras pathway may be a crucial event in
muscle precursor cells leading to ERMS fate, as de-
scribed in mice models [4, 5].
Tumors contain a sub-population of cancer stem cells
(CSCs) or cancer stem-like cells which are considered
to be responsible for tumor initiation, propagation, in-
vasiveness and metastasis [6, 7]. Owing to the lack of
universal markers for the isolation and identification of
CSCs, enrichment of CSCs from tumors or cell lines
through a non-adhesive culture system has been adopted
as a means of characterizing their partial stemness pheno-
type [8–10]. Several CSC markers have been identified in
solid tumors including cell surface markers CD133, CD90,
CD117, CXCR4 and CD166, soluble protein aldehyde de-
hydrogenase 1 (ALDH1), and transcription factor nanog
[6, 11, 12]. In particular, CD133 has been identified as a
central marker of ERMS CSC [13]. In stem cell (SC)
medium, ERMS cell lines form spheres, named rhabdo-
spheres, that are enriched in the CD133 positive popula-
tion and have been shown to be more tumorigenic and
more resistant to commonly used chemotherapies [13].
CXCR4, which plays an important role in chemotactic and
invasive responses in several solid tumors, increases in
ERMS spheres [14]. A high expression of CD133 in hu-
man ERMS samples also correlates with an unfavorable
clinical outcome [13]. Moreover, ALDH1 has been re-
ported to be a potential marker of CSCs in ERMS [15]
and of muscle stem cells that spontaneously undergo
myogenic differentiation [16], as well as a marker of
rapid isolation of the human myogenic progenitors for
cell therapy [17].
Signaling pathways in cancer stem cell biology are
increasingly being used to investigate the mechanisms
underlying the drug resistance, tumor relapse and dor-
mant behavior exhibited by many tumors [18, 19]. The
inhibition of EGFR-mediated MEK/ERK signaling im-
pairs stem cell self-renewal and reduces the propaga-
tion of the DU145 prostate cell line [20]. Moreover,
disruption of K-Ras or downstream signaling in colo-
rectal cancer cell lines impairs CD133 expression [21].
One of the main indicators of the sensitivity of cancer
cells to chemotherapeutic agents is believed to be apop-
tosis, particularly via the intrinsic mitochondrial cascade.
Various integrated signals converge on BAK, an import-
ant effector of intrinsic apoptosis. BAK is negatively
regulated by BMX, a tyrosine kinase, which associates
with and phosphorylates BAK, thereby contributing to
its inactivation [22]. BMX is often overexpressed in can-
cer cells to promote the survival of cancer.
It has been suggested in a previous work that MEK/ERK
signalling is directly involved in the prevention of apop-
tosis [23]. The authors discussed the mechanism under-
lying BAK-mediated mitochondrial apoptosis and MEK/
ERK-mediated inhibition of tyrosine phosphatase, which
affects BAK phosphorylation and activation, thereby con-
tributing to maintain cell survival [23].
Besides playing a role in the inhibition of apoptotic
mechanisms, BMX is also required for maintenance of
stem-like phenotypes in glioblastoma [24].
In ERMS, the main pathways involved in CSC survival
and growth in the tumor environment have not yet been
clearly defined. The MEK/ERK pathway has been shown
to play a critical role in controlling cell growth, radioresis-
tance and differentiative signals in the RD [25]. An inter-
play between ERKs and p38 mitogen-activated protein
kinase (MAPK) has also been hypothesized [26].
In this study, inhibition of MEK/ERK signaling by
U0126 reduces the size and tumorigenicity of the stem-
like RD cell population. Furthermore, U0126 treatment
enhances the inhibitory effect of radiation on stem-like
rhabdomyosarcoma cells by favoring apoptosis. These
findings highlight the potential advantage of using MEK/
ERK inhibitor to target embryonal stem-like rhabdomyo-
sarcoma cells.
Methods
Sphere culture, sphere formation assay, treatments and
radiation exposure
Embryonal rhabdomyosarcoma cell lines, RD and TE671
(HTL97021), were procured from the American Type
Culture Collection and Interlab Cell Line Collection,
respectively.
Alveolar RH30 was obtained from DSMZ (Braunschweig,
Germany). Sphere-forming cells were obtained as described
[27]. Briefly, RD cells were cultured in anchorage-
independent conditions (low attachment flasks or plates,
Nunc) in SC-medium consisting in DMEM:F12 medium
(Gibco-Invitrogen) with progesterone (2 μM), putresceine
(10 μg/ml), sodium selenite (30nM), apo-transferrin
(100 μg/ml) and insulin (50 mg/ml) (all from Sigma-
Aldrich). Fresh human epidermal growth factor (20 ng/ml)
and fibroblast growth factor (20 ng/ml) (PeproTech,
London, UK) were added twice/week until cells formed
floating spheres.
To evaluate the primary sphere formation, cells from
sub-confluent (70–80 %) monolayer cultures were plated
at a density of 100, 500 or 1000 cells in a 24-well culture
plate (Corning Inc, Corning, NY, USA). For the sphere for-
mation assay, the number of primary tumorspheres was
counted. The primary spheres were mechanically dissoci-
ated and re-plated together with residual cell aggregates to
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obtain the second generation of spheres (Additional file 1:
Figure S1).
MEK/ERK inhibitor U0126 (Promega, Madison, WI,
USA) and MAPK p38 inhibitor SB203580 (Calbiochem,
Nottingham, UK) were dissolved in dimethylsulfoxide
(DMSO; Sigma-Aldrich) and used at the concentrations
indicated. For a dose–response curve, RD cells, plated at a
density of 1000 cell/well, as described above, were treated
with varying concentrations of U0126 (1–20 μM) (3 wells
per treatment) and spheres were counted. SB203580 was
used at 2.5 μM, according to previous tests [26]. TE671
and RH30 were treated with 10, 20 or 40 μM U0126.
Radiation was delivered at room temperature using an
x-6 MV photon linear accelerator, as previously de-
scribed [28]. The total single dose of 4 Gy was delivered
with a dose rate of 2 Gy/min using a source-to-surface
distance (SSD) of 100 cm. A plate of Perspex thick
1.2 cm was positioned below the cell culture flasks in
order to compensate for the build-up effect. Tumor cells
were then irradiated placing the gantry angle at 180°.
Non-irradiated controls were handled identically to the
irradiated cells with the exception of the radiation expos-
ure. The absorbed dose was measured using a Duplex
dosimeter (PTW).
Flow cytometer analysis
Stem cell markers in rhabdomyosarcoma cells were
evaluated by staining with monoclonal antibodies conju-
gated with phycoerythrin (PE) anti–CD133 anti–CD90,
anti–CXCR4, anti−CD105, and with allophycocyanin
(APC) anti-CD117(all from BD Biosciences, Buccinasco,
Italy).
Appropriate isotype controls for non-specific binding
were used for each antibody. A minimum of 50,000 events
were acquired for each sample by a flow cytometer
(FACSCalibur, BD Biosciences) using CellQuest software
(BD Biosciences) for data acquisition and analysis.
Cell cycle analysis
A DNAcon3 kit (Dako, Glostrup, Denmark) was used
for DNA staining. Briefly, 1 ml propidium iodide solu-
tion was added to each test tube containing dehydrated
buffer mixture. After 10 min, cells were added to each
tube and incubated at 4 °C for 1 h. Analysis was per-
formed with FACScalibur, and the cell-cycle distribution
was analyzed using Mod-Fit software (Verity Software
House, Topsham, ME, USA).
Aldefluor assay
The stem cell population expressing ALDH enzymatic ac-
tivity was assessed by means of the Aldefluor™ kit (Stem-
Cell Technologies, Vancouver, BC, Canada), according to
the manufacturer’s instructions. Briefly, 1 × 105 cells were
resuspended in Aldefluor assay buffer containing ALDH-
substrate, and incubated for 45 min at 37 °C; a set of cells
was stained using identical conditions with diethylamino-
benzaldehyde, a specific ALDH inhibitor, as a negative
control. Samples were analyzed by means of FACSCalibur,
and the resulting fluorescence profiles were compared.
Immunoblot analysis
Cells were lysed in Tris–HCl 10 mM pH 7.5, 1 % SDS
containing phosphatase and protease inhibitors (Roche,
Mannheim, Germany). Proteins were separated by SDS-
polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane (Schleicher & Schuell, Bio-
Science, Germany) by electroblotting. Immunoblotting
was performed with the following antibodies: anti-
Nanog, anti-ERK, anti-phospho-ERK1/2,anti- myogenin,
anti-αtubulin, anti-GAPDH, anti-DNAPKcs, anti-Rad51,
anti-BMX (all from SantaCruz Biotechnology, Santa
Cruz, CA), anti-phospho-p38 (Cell Signaling Technol-
ogy, Danvers, MA, USA) and anti- myosin heavy chain
(MHC) (MF20 supernatant of hybridoma). Anti-mouse
or anti-rabbit HRP-conjugated antibodies (Bethyl Labora-
tories Inc., Montgomery, TX, USA) were used for ECL
(GE Health Life Sciences, Piscataway Township, NJ, USA)
detection. Signals from protein bands were digitally ac-
quired and quantified using the Chemidoc XRS system
(BIORAD, Brossard, QC, Canada).
Invasion assay
Invasion assay was used to assess the invasive potential
of the cells, according to the standard protocol. Briefly,
cells were plated in the upper chamber of a 24-well
Transwell plate (8 μm pore size filter; Corning Inc.,
Corning, NY, USA) at a density of 80,000 cells/well in
200 μl of SC medium. 750 μl of SC medium containing
10 % FBS was added to the lower chamber as a chemo-
attractant, or SC medium alone as a negative control.
After 24 h at 37 °C, non-invading cells were removed
from the upper surface of inserts with a cotton swab and
invaded cells were fixed with 4 % paraformaldehyde and
stained. The number of cells that invaded the filter was
counted using a bright-field microscope. Ten randomly
selected fields were counted for each filter and the ex-
periments were carried out twice in triplicates.
Apoptosis assay
The Annexin/V-PI assay was carried out using the
Annexin V-FITC Apoptosis Detection Kit (MERK Milli-
pore). Rhabdospere RD cells were harvested and the pel-
lets were immediately resuspended in the binding buffer
provided. Cells were stained with 5 μl of FITC Annexin
V and 5 μl of PI. The mixture was left to incubate at
room temperature for 15 min and then was acquired by
FACSCalibur (BD Biosciences) and analyzed using Cell-
Quest software (BD Biosciences).
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NOD/SCID mice transplantation
NOD/SCID mice were bred and maintained under defined
conditions at the Experimental Animal Welfare Sector of
the Istituto Superiore di Sanità, Rome, Italy. All animal
procedures complied with the European Community Dir-
ective on the welfare of experimental animals (Directive
2010/63/EU) upon approval of the protocol by the Institu-
tional Animal Experimentation Committee. Equal num-
bers (2× 106 cells) of adherent RD parental cells or
rhabdosphere-derived cells suspended in 100 μl of phos-
phate buffered saline were subcutaneously injected into
four- to six-week-old NOD/SCID female mice. Viability of
the injected cells was confirmed by trypan blue (Sigma)
staining prior to injection. Intraperitoneal injections of
U0126 started when tumors reached a volume of 80–
100 mm3. U0126 solution was prepared in DMSO as a
stock solution of 10 mmol/L, and the amount of drug
(25 μmol/Kg/mouse) to be injected into a set of mice
was diluted with carrier solution (40 % DMSO in
physiologic solution). The U0126 dose used here had
previously been tested and found to be non-toxic in
mice and to down-regulate ERK1/2 in tumors [25].
U0126 was administered 3 times per week. This proto-
col was chosen because full inhibition of ERK activation
is guaranteed in vivo after 24 h and was documented
after this time [25]. Four weeks after the beginning of
treatment, the mice were killed by cervical dislocation
and the tumors removed and weighed.
For U0126 pre-treatment, RD cells were cultured in
SC medium in the presence of 10 μM U0126 for 15 days,
followed by the transplantation of 2 × 106 cells into the
flank of NOD/SCID mice. Following cell injection, mice
did not receive U0126 for the rest of the in vivo period.
Four weeks after tumor appearance, the mice were killed
by cervical dislocation and the tumors removed and
weighed.
Assessment of in vivo response to treatments
The effects on tumor growth of different treatments
were evaluated by measuring the following: (1) tumor
volume measured during and at the end of the experi-
ment. Tumors were measured with a vernier caliper
every 4 days and their volume, expressed in mm3, was
calculated as length x (width)2/2. (2) Tumor weight
measured at the end of experiment; (3) tumor progres-
sion, defined as an increase greater than 100 % of the
tumor volume at the beginning (80–100 mm3) of the
U0126 treatment delivered intraperitoneally; (4) time to
progression. In the experiments in which the incidence
of tumor development was studied, the occurrence of
this event was defined as the appearance of a measur-
able (80–100 mm3) subcutaneous tumor lesion at the
site of cell injection.
Dissociation of tumor into single-cell suspension
For the FACS analysis, cells from xenograft tumors were
obtained by means of the tissue dissociation protocol that
combines mechanical and enzymatic approaches. Isolated
tumor was minced with a sterile scalpel and digested with
a solution of 1.5 mg/ml collagenase II (Gibco,) and 20 μg/
ml DNAse I (Sigma) added to the tumor during mincing
to facilitate tumor dissociation. After 2 h of incubation at
37 °C, cells were dissociated, washed and processed for
FACS analysis.
Statistical analysis
Continuous variables were summarized as the mean and
S.D. or 95 % CI for the mean. Statistical comparisons be-
tween controls and treated groups were established by
carrying out the Student’s t test for unpaired data (for two
comparisons). Dichotomous variables were summarized
by absolute and/or relative frequencies. For dichotomous
variables, statistical comparisons between control and
treated groups were performed by means of the exact
Fisher’s test. The incidence of tumor development and
tumor progression were analyzed by using Kaplan-Meier
curves and Gehan’s generalized Wilcoxon test. Curves
were compared by means of the log rank test and deter-
mination of the hazard ratio (HR). All the tests were two-
sided and were determined by Monte Carlo significance. P
values <0.05 were considered statistically significant. SPSS
(statistical analysis software package, IBM Corp., Armonk,
NY, USA) version 10.0 and StatDirect (version. 2.3.3., Stat-
Direct Ltd, Altrincham, Manchester, UK) were used for
the statistical analysis and graphic presentation.
Results
MEK/ERK inhibition affects the in vitro stem cell-like
phenotype in embryonal, but not alveolar,
rhabdomyosarcoma cell lines
RD cells grown in non-adherent conditions in the pres-
ence of SC-medium formed floating rhabdospheres in
10–15 days (Fig. 1a, middle panel). Rhabdosphere for-
mation dependence on cell number was tested (Additional
file 2: Figure S2).
The size of the stem-like population in rhabdospheres
was evaluated using flow cytometry by assaying the per-
centage of the stem cell markers CD133, CXCR4 and
ALDH (Fig. 1b). The percentage of CD133 positive cells
was significantly higher in rhabdospheres than in adherent
cells (20.2 % ± 5.4 vs 4.8 % ± 2.4; p < 0.01) and CXCR4
(17.1 % ± 4.6 vs 3.2 % ± 2.0; p < 0.01) and ALDH (7.6 % ±
3.7 vs 20.3 % ± 5.7; p <0.05) positive cells (Fig. 1b). No dif-
ferences were observed in CD90, CD117, CD105 and
CD166 expression (Additional file 3: Figure S3).
To ascertain whether the enriched RD stem-like popula-
tion in rhabdospheres displayed a higher tumorigenic po-
tential than the parental RD cell line, as has been reported
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elsewhere [13], adherent (1.97 % CD133 positive cells)
or rhabdosphere cells (12.5 % CD133 positive cells)
were injected into NOD/SCID mice (Additional file 4:
Figure S4A). Tumors derived from rhabdosphere cells
grew 1 month earlier and were larger than those in-
duced by adherent cells (Additional file 4: Figure S4B),
thereby suggesting that rhabdospheres were enriched in
cancer stem-like cells characterized by a higher degree
of in vivo tumorigenicity.
The role of the MEK/ERK pathway in maintaining the
ERMS stem-like population phenotype was investigated.
RD cells were cultured in SC-medium with or without
U0126, a MEK/ERK inhibitor. 10 μM U0126 drastically
reduced rhabdosphere formation (Fig. 1a). The inhib-
ition of rhabdosphere formation was dose-dependent,
10 μM being the minimal dose displaying the maximum
effect on rhabdosphere inhibition (Additional file 5:
Figure S5). In SC-medium, U0126 treatment inhibited,
Fig 1 Expression of stem cell phenotype in RD cells and its inhibition by U0126. a Representative microphotographs of RD cells in adherent
conditions (Ad) and in SC medium after 15 days of incubation in the absence (rhabdospheres, SC-mSPH) or in the presence of 10 μM U0126
(SC-m + U) (Bar = 100 μm). b Histograms of percentage of CD133, CXCR4 and ALDH positive cells determined by FACS analysis. Values represent the
mean ± SD of 5 independent experiments. Statistical significance is indicated (**p < 0.01,*p < 0.05). c-d Western blot analysis of protein lysates from
adherent RD cells (Ad) and RD in SC medium without (SC-mSPH) or with 10 μM U0126 (SC-m+ U) at 15 days. c The expression levels of Nanog, ERK1/
2-PO4 and ERK1/2 were analyzed. Protein bands were quantified by densitometry with respect to GAPDH. Representative experiment is shown. d The
expression levels of myogenin and myosin heavy chain (MHC) were analyzed. Protein bands were quantified with respect to α-tubulin. Representative
experiment is shown (out of three). e Cell invasion of RD in SC medium without (SC-mSPH) or with 10 μM U0126 (SC-m + U). Representative
experiment is shown. Statistical significance is indicated (*p < 0.05)
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by 85 %, the increase in the number of both CD133
(3.1 % ± 0.7 vs 20.2 % ± 5.4; p < 0.01) and CXCR4 (2.4 %
± 1.2 vs 17.1 % ± 4.6; p < 0.01) positive cells (Fig. 1b). By
contrast, ALDH activity was further increased by U0126
(35.5 % ± 5.2 vs 20.2 % ± 5.4; p < 0.05) (Fig. 1b).
The expression of the stem cell marker Nanog in
rhabdosphere cells, evaluated by immunoblot analysis,
increased by about 70 % in comparison with adherent
cells. In the presence of U0126, Nanog expression was
inhibited by 65 % in comparison with untreated rhabdo-
spheres (Fig. 1c). Phospho-active ERK1/2 levels were
enhanced 4-fold in cells cultured in SC-medium in com-
parison with adherent cells, whereas U0126 treatment
induced 50 % inhibition (Fig. 1c) that persisted up to
15 days (Additional file 6: Figure S6). Since MEK/ERK
inhibition induces myogenic differentiation in RD cells,
the expression of the differentiative markers myogenin and
MHC was also analyzed in cells cultured in SC-medium in
the presence of U0126. U0126 induced myogenin and
MHC expression (Fig. 1d).
To investigate the effect of MEK/ERK on invasive-
ness, we probed rhabdosphere cells and U0126-treated
cells in SC medium in an in vitro invasion assay. Inva-
siveness of MEK/ERK inhibited RD cells resulted de-
creased by 37 % in comparison with that of the
rhabdosphere cells (Fig. 1e).
Rhabdosphere inhibition was also observed in TE671,
another embryonal rhabdomyosarcoma cell line, though
it required a higher concentration of U0126 (40 μM)
(Fig. 2a).
In TE671, the stem cell markers CD133 and CXCR4
were highly expressed, while U0126 treatment strongly
Fig. 2 Expression of stem cell phenotype in other cell lines and effects of U0126. a and d Representative microphotographs of TE671 or RH30
cells in SC medium after 7 days of incubation in the absence (rhabdospheres, SC-mSPH) or in the presence of 40 μM U0126 (SC-m+ U) (Bar = 100 μm).
b and e Histograms of percentage of CD133 and CXCR4 positive cells determined by FACS analysis. Values represent the mean ± SD of 3 independent
experiments. Statistical significance is indicated (*p < 0.05). c Western blot analysis of protein lysates from TE671 in SC medium without (SC-mSPH) or
with different concentrations of U0126 (10–40 μM) (SC-m + U) at 7 days. f Western blot analysis of protein lysates from RH30 cells in SC
medium without (SC-mSPH) or with 40 μM of U0126 (SC-m + U) at the times indicated. The expression levels of ERK1/2-PO4 and ERK1/2 were
analyzed. ERK1/2-PO4 bands were quantified by densitometry and compared with ERK1/2
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reduced the number of both CD133 (75 % ± 14.5 vs
6.7 % ± 4,5; p < 0.01) and CXCR4 (79 % ± 2.2 vs 14 % ±
6.8; p < 0.01) positive cells (Fig. 2b). Immunoblot ana-
lysis showed that ERK inhibition mirrors the inhibition
of tumorsphere formation (Fig. 2c).
Since dysregulation of the Ras pathway is preferentially
associated with ERMS and is responsible for the constitu-
tive activation of MEK/ERK pathways, we included RH30,
a rhabdomyosarcoma cell line that is negative for Ras mu-
tations [29], to study the efficacy of MEK/ERK inhibition
in cells lacking the constitutive activation of Ras/MEK/
ERK pathways. Treatment with U0126 (10–40 μM) did
not inhibit either rhabdosphere formation or CD133 and
CXCR4 expression (Fig. 2d, e). Immunoblot analysis
showed that ERK1/2 phosphorylation is transiently inhib-
ited by U0126 treatment (30 min.), but recovers within
3 h (Fig. 2f).
MEK/ERK and MAPK p38 pathway inhibition have
opposite effects on RD stem-like phenotype
We showed that U0126 activates MAPK p38 in RD cells
by inducing MEK/ERK inhibition [26]. To verify whether
inhibition of RD stemness by U0126 is due to inhibition
of phospho-active ERK1/2 and/or to MAPK p38 activation,
we added SB203580 (SB), a MAPK p38-activity inhibitor,
to the SC-medium at a concentration of 2.5 μM. MAPK
p38 inhibition accelerated rhabdosphere formation, which
appeared 5–7 days earlier than in cells cultured without SB
(Fig. 3a). These effects were counteracted by SB and
U0126 co-treatment (Fig. 3a).
The cell cycle analysis (Fig. 3a) and cell counting (Fig.
3b) showed the proliferative effects of SB treatment, which
were attenuated by concomitant U0126 treatment
(Figs. 3a, b). The analysis of CD133 positive population at
day 7 did not reveal any major differences between RD
grown in SC-medium in the absence and that grown in
the presence of SB (Fig. 3c). Furthermore, SB treatment
reduced the percentage of CXCR4 positive cells (5 % ± 3.3
vs 21.2 % ± 2.2) (Fig. 3c). In SB and U0126 co-treatment,
the expression of CD133 and CXCR4 remained un-
changed when compared with U0126 treatment alone
(Fig. 3c). Nanog expression increased in the presence of
SB on its own (Fig. 3d) but dropped markedly in the pres-
ence of both SB and U0126, thus suggesting a predomin-
ant effect of ERK inhibition. This hypothesis is supported
by the analysis of the phospho-active ERK1/2 expression
levels (Fig. 3d). In SB-treated cells, phospho-active ERK1/
2 levels were considerably higher than in untreated RD
cells, whereas when SB and U0126 were combined,
phospho-active ERK1/2 levels were the same as those ob-
served in U0126-treated RD cells.
In U0126-treated cells, MAPK phospho-active p38
levels were higher than in untreated RD cells and were
inhibited in SB and U0126 treated cells. As expected,
myogenin levels were increased by U0126 and inhibited
by SB treatments. Nevertheless, myogenin levels in SB
and U0126 treated cells remained above those observed
in control untreated cells (Fig. 3d).
U0126 impairs In vivo tumorigenicity of RD stem-like cells
The effects of MEK/ERK inhibition on tumorigenic poten-
tial were evaluated by inducing xenografts in NOD/SCID
mice. For this purpose, RD cells in SC-medium were
chronically (15 days) treated with U0126 before injection
or left untreated. The percentage of CD133 positive cells
in U0126 chronically-treated RD cells was lower (1.6 %)
than in rhabdosphere untreated cells (27.3 %) (Fig. 4a). RD
pre-treatment with U0126 postponed the mean time to
tumor development by 6.7 weeks (Fig. 4b). These data are
in agreement with those that emerge from the Kaplan-
Meier curves, according to which tumor development oc-
curred significantly more slowly in U0126 in vitro pre-
treated cells (HR = 0.43; CI 95 % 0.169 to 0.96; p = 0.0152)
than in rhabdosphere untreated cells (Fig. 4c). Indeed, the
likelihood of developing a tumor in mice subcutaneously
injected with U0126-pretreated RD cells was lower (57 %)
(Figs. 4b, d). Interestingly, 4 out of the 11 (36.4 %) U0126
pre-treated RD cells had not developed tumors 24 weeks
after cell injection, whereas all the animals injected with
rhabdosphere cells had developed tumors after 17 weeks
(Fig. 4c). A comparative analysis of tumor xenografts
4 weeks after their appearance showed that tumors in-
duced by U0126 pre-treated RD cells were smaller than
those induced by rhabdosphere cells (Fig. 4e).
The in vivo effect of MEK/ERK inhibition was also
assayed by treating mice bearing xenografts induced by
rhabdosphere cells (25 % CD133 positive cells) (Fig. 5a)
with an intraperitoneal injection of 25 μmoles/kg of
U0126 when the tumor mass reached a volume of be-
tween 80 and 100 mm3.
The mean time to tumor progression was delayed by
about 0.8 weeks in the group of mice treated with U0126
compared with mice with rhabdosphere tumors (Figs. 5b,
c). All the mice treated with U0126 displayed tumor pro-
gression within 3.5 weeks of reaching a volume of 80–
100 mm3. Tumor progression in the rhabdosphere group
was instead observed within 2.9 weeks of reaching a vol-
ume of 80–100 mm3. Mice treated with U0126 were less
likely (54 %) to develop tumors (HR = 0.46; CI 95 % 0.17
to 0.96; p = 0.0094) (Fig. 5d). Tumor analysis 4 weeks after
U0126 treatment showed that tumor xenografts from
U0126-treated mice were smaller than those from control
mice (Fig. 5e).
Comparing results of the two in vivo experiments, the
greatest reduction in tumor volumes was observed in xe-
nografts derived from U0126 pre-treated cells (Fig. 6a).
We then compared CD133 and CXCR4 positive popula-
tions in dissociated xenografts from U0126-pretreated
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Fig 3 (See legend on next page.)
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cells and intraperitoneal U0126-treated mice. The results
show a significant increase (2 fold) in the size of the
CD133 positive population in tumors induced by U0126
pre-treated RD cells compared with those induced by
rhabdosphere cells. By contrast, the size of the CD133
positive population in dissociated xenograft cells from in-
traperitoneal U0126-treated mice was smaller (0.45 fold)
than in those induced in mice treated with vehicle alone
(Fig. 6b). A significant increase (1.8 fold) was observed in
the size of the CXCR4 positive population in xenografts
Fig. 4 Delays of tumor development in xenografts from U0126 in vitro pre-treated cells. a FACS analysis of CD133 positive cells in rhabdosphere
cells (SC-mSPH) and 10 μM U0126 treated cells in SC medium (SC-m + U) before subcutaneously injection. b-e Tumor development of xenografts
from rhabdosphere cells (SC-mSPH) and U0126 treated cells in SC medium (SC-m + U). b Mean time to tumor development. c Analysis of tumor
development by Kaplan-Meier. d Hazard Ratio (HR) with comparison of tumor development curves by Logrank test. e Tumor volume and tumor
weight of xenografts at the end of the experiment (4 weeks after tumor development); bars represent mean ± S.D. Statistical significance is
indicated (**p < 0.01)
(See figure on previous page.)
Fig 3 Effects of inhibition of p38 on sphere formation, stem and differentiative markers expression. RD cells were incubated in SC medium for
7 days (CTR) in the absence or in the presence of 2.5 μM SB203580 (SB) without or with 10 μM U0126 (SB + U). a Microphotographs (Bar = 100 μm)
and cell cycle analysis of a representative experiment (out of three). b Histogram with cell numbers determined by cell counting. c Histograms of
percentage of CD133 and CXCR4 positive cells determined by FACS analysis. Values represent the mean ± SD of 3 independent experiments. Statistical
significance is indicated (**p < 0.01). d Western blot analysis of protein lysates. The expression levels of Nanog, ERK1/2-PO4, ERK1/2, myogenin, p38-PO4
and p38 were analyzed. Protein bands were quantified by densitometry with respect to GAPDH, ERK1/2
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derived from U0126-pretreated RD cells (Fig. 6c), whereas
a non-significant decrease was observed in the size of the
CXCR4 positive population in xenografts derived from in-
traperitoneal U0126-treated mice (Fig. 6c).
Effect of U0126 and radiation treatments in rhabdosphere
maintenance and apoptosis
The rationale of rhabdosphere treatment with U0126
and/or radiation lies in the possibility it offers of target-
ing an enriched stem-like cell population. The use of
two concentrations of U0126 allowed us to assess the
minimal dose of inhibitor required to obtain the maximal
effects when combined with radiotherapy. Treatment with
10 μM U0126 led to a clear disassembly of cells from
rhabdospheres. Less evident disassembly was observed
using a reduced U0126 concentration (2 μM) (Fig. 7a).
Combined U0126 (2 or 10 μM) and radiation (4Gy) treat-
ment enhanced the effect of sphere disassembly, further
reducing the number and size of the spheres (Fig. 7a).
The analysis of the stem cell markers showed that ei-
ther 2 μM U0126 treatment or radiation treatment
slightly reduced the expression of CD133 and more
markedly reduced that of CXCR4 (Fig. 7b). By contrast,
combined treatment greatly reduced the expression of
both stem cell markers. CD133 was reduced 10 fold
(16.9 % ± 6.4 vs 1.6 % ± 0.3) and CXCR4 11 fold (7.1 %
Fig. 5 U0126 inhibits the growth of rhabospheres-derived xenografts. a FACS analysis of CD133 positive cells in rhabdosphere cells (SC-mSPH)
before subcutaneously injection. b-e Mice bearing tumor xenografts derived from rhabdosphere cells were treated with vehicle (group: SC-mSPH)
or with U0126 by intraperitoneal injection at 25 μmol/kg/mouse (group: SC-mSPH, U0126 i.p.); tumor size was assessed every 4 days. b Mean time
of tumor progression. c Analysis of tumor progression by Kaplan-Meier curves. d Hazard Ratio (HR) with comparison of growth curves by Logrank
test. e tumor volume and tumor weight at the end of the experiment (4 weeks of treatment). Bars represent mean ± S.D. Statistical significance is
indicated (*p < 0.05)
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± 4.4 vs 0.6 % ± 0.2). Treatment with 10 μM U0126
alone markedly reduced both CD133 and CXCR4 (1.4
± 0.8 and 2.9 ± 1.8, respectively), and to an even greater
extent when combined with radiation (0.45 % ± 0.3 and
0.8 % ± 0.3, respectively) (Fig. 7b).
We also analyzed the expression of Nanog and compo-
nents of DNA repair machinery, such as Rad51 and
DNA-PKcs, in rhabdospheres.
The results show that Nanog expression levels were
unchanged following treatment with 2 μM U0126 and
were reduced following treatment with 10 μM U0126.
Nanog expression was increased slightly by radiation,
but was inhibited by either concentration when com-
bined with radiation (Fig. 7c).
The expression levels of DNA-PKcs were reduced by
both concentrations of U0126 regardless of the presence
or absence of radiation, the degree of inhibition being
more pronounced in Rad51 expression following com-
bined radiation and 10 μM U0126 treatment (Fig. 7c).
Since BMX may help to protect cells from apoptosis in-
duced by radiation [30], we analyzed BMX expression in
rhabdosphere after radiation in the presence or absence of
U0126. The result shows that BMX expression is down-
regulated at an even lower concentration (2 μM) of U0126
when combined with radiation, as demonstrated by the
analysis of apoptotic cells (Additional file 7: Figure S7).
Discussion
Cancer stem cell research is becoming increasingly im-
portant in the investigation of the development, spread,
resistance to chemo- and radio-therapy and relapse of
cancer.
We previously demonstrated, both in vitro and in vivo,
the responsiveness of the RD cell line to MEK/ERK in-
hibition, which induces growth arrest, myogenic differ-
entiation, radiotherapy sensitization and tumor growth
impairment [25, 28]. On the basis of these data, we de-
cided to assess the contribution of the MEK/ERK path-
way in controlling the cancer stem-like compartment in
the ERMS cell system.
It is generally agreed that tumorspheres enriched in
cancer stem-like cells are highly tumorigenic [13, 27, 31,
32]. By culturing RD cells in SC-medium, we obtained
rhabdospheres enriched in positive CD133, CXCR4,
ALDH and Nanog stem-like cells that are highly tumori-
genic in vivo. These results are consistent with those
reported in previous studies [13–15].
Since Ras/ERK is an upstream pathway of CD133 ex-
pression [21, 33], the use of U0126, a MEK/ERK inhibi-
tor, proved useful to study the dependence of a stem
cell-like population on the MEK/ERK pathway. We used
U0126 to demonstrate, for the first time, the critical
contribution made by MEK/ERK signaling to the cancer
stem-like phenotype in the RD cell line. Indeed, sphere
formation is inhibited by U0126, in a dose-dependent
manner, in the embryonal RD cell line though not in the
Ras negative alveolar RH30 cell line. The RH30 cell line
does not exhibit persistent ERK inhibition by U0126
whereas it does exhibit very low levels of CD133, thus
suggesting that other pathways underlie the alveolar
stem cell-like phenotype.
Fig. 6 Fold variation of volume and stem cell markers expression in
tumor xenografts. a Tumor xenografts volume from rhabdosphere
cells (SC-mSPH), U0126 treated cells in SC medium (SC-m + U) and
rhabdosphere cells after U0126 intraperitoneal injection (SC-mSPH,
U0126 i.p.) at the end point (4 weeks after tumor development).
b CD133-positive cells and c CXCR4 positive cells after digestion
into single cell suspension of tumor xenografts (n = 3,
**p < 0.01, *p < 0.05)
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In rhabdospheres derived from RD cells, the stem cell
markers CD133, CXCR4 and Nanog were enhanced
and were dramatically inhibited by U0126 treatment,
whereas ALDH activity was increased by MEK/ERK in-
hibition. This finding is in agreement with a recent re-
port showing that high ALDH1 activity is related to the
myogenic potential of muscle precursors [34]. It has
also been demonstrated that the induction of myogenic
differentiation occurs spontaneously in myogenic pre-
cursors that highly express ALDH1 [16]. The increased
ALDH activity observed under MEK/ERK inhibition in
the system we adopted may indeed be related to myo-
genic differentiation. In this regard, the differentiative
markers myogenin and MHC are enhanced by the
U0126 treatment of RD cells in SC-medium. We may
therefore speculate that MEK/ERK pathway inhibition
induces molecular reprogramming, which rescues the
myogenic precursor phenotype in rhabdomyosarcoma
cancer stem-like cells.
Together these data strongly suggest that the differen-
tiation boost resulting from MEK/ERK inhibition turns
off cancer stem-like phenotype expression.
Published studies by us and other authors have
shown that MAPK p38 plays a pivotal role in myo-
genic differentiation [26, 35]. Here we found that in-
hibition of the differentiative action of MAPK p38
significantly enhances the expression of Nanog and
phospho-active ERK1/2, correlates with an increased S
phase of the cell cycle and accelerates sphere forma-
tion. The size of the CD133 positive cell population
was not affected markedly under MAPK p38 inhibition
in this study, and that of the CXCR4 positive population
actually decreased. By contrast, Nanog and phospho-
active ERK1/2 were significantly enhanced, thereby sug-
gesting that they play a major role in rhabdosphere
formation. These results agree with those recently re-
ported on the role of Nanog in ERMS as an inducer of
sphere formation, as an important gene for tumor
promoting properties and as a prognostic marker for
ERMS patients [36].
The positive effects of MAPK p38 inhibition on the
stem-like phenotype are reverted by MEK/ERK inhib-
ition when treatment with inhibitors is concomitant,
thereby demonstrating that chronic MEK/ERK inhibition
Fig. 7 Effects of radiation on rhabdosphere cells and in combination with U0126. Radiation (RT) or/and 2 or 10 μM U0126 were provided after
spheres formation (SC-mSPH). Samples were analyzed after 6 days. a Representative microphotographs. b Histograms of CD133 and CXCR4
positive cells determined by FACS analysis. Values represent the mean ± S.D. of 3 independent experiments (**p < 0.01, *p < 0.05). c Western blot
analysis of Nanog, DNA-PKcs, Rad51 and BMX in protein lysates. Protein bands were quantified by densitometry with respect to GAPDH or α-tubulin. A
representative experiment is shown
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strongly impairs the stem-like phenotype in embryonal
rhabdomyosarcoma.
The relevance of the active MEK/ERK pathway in can-
cer stem-like cells with tumor initiating properties is dem-
onstrated by the significant delay in tumor development
(11.4 vs 18.1 weeks) and reduced tumor size displayed by
xeno-transplanted RD cells pre-cultured in the presence
of the MEK/ERK inhibitor. It is noteworthy that our data
showing that rhabdospheres express high ALDH activity,
which is further increased by U0126 treatment, are only
partially in agreement with those of other authors [15],
who reported that ALDH1 is a marker of cancer stem cells
in ERMS. This suggests that ALDH activity is sensitive to
induced signaling. Indeed, U0126-treated cells that
strongly express ALDH do not appear to play a role in
early tumor initiation and the development of tumor
masses, which would be expected to be larger than those
of untreated rhabdospheres. The fact that tumor develop-
ment is delayed and the tumors themselves are smaller
may mean that the subpopulation that expresses a high
degree of ALDH activity does not contribute to the
tumorigenicity of cancer stem-like cells if the active ERK
pathway is absent but undertakes the myogenic precursor
program. This hypothesis is supported by the low expres-
sion level of CD133 and CXCR4 in U0126-pre-treated
cells and correlates strongly with the delay in tumor devel-
opment that occurred without any further U0126 being
added. It is noteworthy that, at the end point, the number
of CD133 and CXCR4 positive cells in this tumor popula-
tion was two folds that in xenografts induced by rhabdo-
spheres. This finding appears to be in contrast to the delay
in tumor development and warrants further investiga-
tion. Moreover, the intraperitoneal U0126 treatment of
mice xeno-transplanted with rhabdosphere cells in-
hibits tumor growth by about 50 %. The responsiveness
of rhabdosphere-derived tumors to the MEK/ERK in-
hibitor in developing xenografts might be consequent
to the reduction in the size of the CD133 population
even in in vivo conditions. On the basis of all these
in vivo data, continuous treatment with the MEK/ERK
inhibitor might help to maintain low levels of CD133
and CXCR4 positive cells.
Following Ras activation, the MAPK pathway has been
reported to contribute to the invasive potential of cancer
cells [37]. Other authors have demonstrated that increased
Caveolin 1 expression enhances ERK pathway activation
and potentiates invasiveness of RD cells [38]. Further-
more, it is worth recalling data from others [39–41] that
suggest the role of CD133 and CXCR4 content in sustain-
ing high metastatic capacity in in vitro and in vivo model
of some tumor types. However, the metastatic activity of
cancer stem cells is a multistep process, that includes the
invasiveness, but is not completely performable in vitro.
The reduced invasion potential of U0126-treated cells in
SC medium compared with rhabdosphere cells is in keep-
ing with the reduced expression level of CXCR4 and
CD133 in U0126-treated cells. Our result indicates that in
RD cancer like stem cells invasion potential is a property
that depends on ERK pathway.
Targeting MEK/ERK pathway to reduce the chemo-
and radio-resistant CD133 positive cell population [13]
may have important implications in the treatment of
ERMS.
Indeed, the radioresistance phenotype of cancer stem
cells might be the cause of cancer relapse [42, 43]. The
reduction of CD133 positive population might have a
beneficial effect on radiation efficacy given that in some
cases in CD133 positive cells active ERKs is enhanced by
radiation [44].
A combination of radiotherapy and chemotherapy is
one approach currently being used to treat rhabdomyosar-
coma. Within this context, the rationale underlying the
treatment of rhabdospheres using U0126 was the
hypothesis that MEK/ERK inhibition enhances radiosensi-
tivity in the presence of an enriched cancer stem-like
population. Radiation or U0126 treatment on their own
modify the integrity of rhabdospheres, alter the percentage
of stem cell markers and reduce the DNA machinery
components levels, though radiation alone is less effective.
Combined therapy induces a more pronounced dismant-
ling of rhabdospheres and inhibits the expression of stem
cell markers and Rad51. Bearing in mind that Rad51 ex-
pression is highly sensitive to MEK/ERK inhibitor [45],
the markedly reduced levels of Rad51 and DNA-PKcs ob-
served in U0126-treated rhabdospheres indicate that
MEK/ERK inhibition impairs DNA repair mechanisms,
thereby rendering RD cells more sensitive to radiation.
The ability of MEK/ERK pathways to orchestrate the
complex mechanism of survival in tumor cells, includ-
ing resistance to radiation, is also demonstrated here by
the MEK inhibitor-mediated down-regulation of BMX,
whose absence is known to relieve cells from the nega-
tive regulation of apoptosis [22]. Therefore, the MEK/
ERK-dependent inhibition of BMX expression [23] may
be involved in the enhanced sensitivity of RD cells to
radiation.
Conclusions
Our results indicate that the MEK/ERK pathway plays a
prominent role in maintaining the stem-like phenotype
of RD cells. Furthermore, the MEK/ERK pathway inhib-
ition makes RD cells more sensitive to radiation.
In conclusion, therapeutic strategies aimed at targeting
cancer stem cells that are resistant to traditional cancer
therapies may benefit from MEK/ERK inhibition combined
with radiotherapy, and thus offer a promising therapy for
embryonal rhabdomyosarcoma.
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Additional files
Additional file 1: Figure S1. CD133 positive population in primary (first
generation) and secondary (second generation) rhabdospheres. CD133
positive cells have been determined by FACS. No major differences in
size of CD133 positive population were detected between the two
generation of rhabdospheres. (TIF 395 kb)
Additional file 2: Figure S2. Histogram of rhabdospheres formation
dependent on number of cells. RD seeded at 500 or 1,000 cells/well
in SC-medium (three replicates/sample). Rhabdosphere were counted
at indicated times. The sphere numbers are displayed as mean ± S.D.
(TIF 122 kb)
Additional file 3: Figure S3. Results of FACS analysis of the levels of
CD90, CD117 and CD105 positive populations, which remain unchanged
in SC-medium with respect to adherent condition. The percentage is
displayed as mean ± S.D. of 3 experiments. (TIF 139 kb)
Additional file 4: Figure S4. Tumorigenic assay of rhabdosphere cells.
A) FACS analysis of CD133 positive cells in adherent and in rhabdosphere
cells (SC-mSPH) before subcoutaneously injection (pre-injection); B) histogram
showing the tumor development and volumes of xenografts from adherent
(Ad) or rhabdosphere cells (SC-mSPH), (n= 6, *p> 0,05). (TIF 341 kb)
Additional file 5: Figure S5. U0126 dose/response of rhabdospheres
inhibition. Histogram of two independent experiments of RD cells seeded
in SC-medium (1,000 cells/well, three replicates per treatment) without or
with indicated concentration of U0126. At13th day 1/3 of volume of fresh
SC-medium containing the indicated U0126 concentration was added.
Rhabdospheres were counted at indicated times. The sphere numbers
are displayed as mean ± S.D. (TIF 122 kb)
Additional file 6: Figure S6. Persistent phospho-ERK1/2 (ERK1/2-P)
down regulation by U0126. Western blot analysis of protein lysates from
RD in SC-medium without or with 10 μM U0126 at indicated times. The
expression of ERK1/2-P was analysed and quantified by densitometry with
respect to ERK/1/2. Representative experiment is shown. (TIF 385 kb)
Additional file 7: Figure S7. Radiation (RT) or/and 2 μM U0126 were
provided after RD rhabdophere spheres formation. Analysis of cell death
by flow cytometric detection of Annexin-V staining of samples analyzed
after 6 hours of treatment. (TIF 78 kb)
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